These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3731685)

  • 21. Hydrochlorothiazide and triamterene with sustained-release oxprenolol in the treatment of hypertension.
    Backhouse CI; Rowley-Jones D; Spencer-Mills L
    Curr Med Res Opin; 1986; 10(3):196-202. PubMed ID: 3731824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperkalemia in diabetes mellitus. Effect of a triamterene-hydrochlorothiazide combination.
    Hollenberg NK; Mickiewicz C
    Arch Intern Med; 1989 Jun; 149(6):1327-30. PubMed ID: 2730251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double-blind comparison of triamterene plus hydrochlorothiazide and spironolactone plus hydrochlorothiazide in the treatment of hypertension.
    Cocke TB; Fisch S; Gilmore HR; Okun R; Tamagna IG; Wipplinger K
    J Clin Pharmacol; 1977; 17(5-6):334-8. PubMed ID: 323298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lithium toxicity induced by triamterene-hydrochlorothiazide.
    Mehta BR; Robinson BH
    Postgrad Med J; 1980 Nov; 56(661):783-4. PubMed ID: 7267481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of triamterene.
    Mutschler E; Gilfrich HJ; Knauf H; Möhrke W; Völger KD
    Clin Exp Hypertens A; 1983; 5(2):249-69. PubMed ID: 6831748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dyazide composition.
    Akman D
    Ann Intern Med; 1976 Dec; 85(6):827. PubMed ID: 999119
    [No Abstract]   [Full Text] [Related]  

  • 27. Hydrochlorothiazide/triamterene combination: once daily in the treatment of hypertension.
    Zacharias FJ; Cornhill J
    Br J Clin Pract; 1984 May; 38(5):185-7. PubMed ID: 6733013
    [No Abstract]   [Full Text] [Related]  

  • 28. Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide).
    Hollenberg NK; Mickiewicz CW
    Am J Cardiol; 1989 Jan; 63(4):37B-41B. PubMed ID: 2911994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood pressure lowering and potassium conservation by triamterene-hydrochlorothiazide and amiloride-hydrochlorothiazide in hypertension.
    Maxwell MH; Brachfeld J; Itskovitz H; Lunn JA; Moser M; Zawada ET
    Clin Pharmacol Ther; 1985 Jan; 37(1):61-5. PubMed ID: 3880686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of mild-to-moderate hypertension: comparison between a calcium-channel blocker and a potassium-sparing diuretic.
    Boulet AP; Chockalingam A; Fodor JG; Laplante L; Houde M; Lenis J; Logan AG; Robitaille MN; Ryan D; Spénard J
    J Cardiovasc Pharmacol; 1991; 18 Suppl 9():S45-50. PubMed ID: 1725543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of muzolimine and of a combination of hydrochlorothiazide/triamterene in healthy subjects and in nephrotic patients.
    Riechers G; Futerova M; Hanisch M; Ritter W; Kühn K
    Z Kardiol; 1985; 74 Suppl 2():103-8. PubMed ID: 4002782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of formulation and food on the absorption of hydrochlorothiazide and triamterene or amiloride from combination diuretic products.
    Williams RL; Mordenti J; Upton RA; Lin ET; Gee WL; Blume CD; Benet LZ
    Pharm Res; 1987 Aug; 4(4):348-52. PubMed ID: 3508542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and pharmacodynamics of triamterene and hydrochlorothiazide and their combination in healthy volunteers.
    Möhrke W; Knauf H; Mutschler E
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):447-52. PubMed ID: 9352394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The true composition of kidney stones passed during triamterene therapy.
    Sörgel F; Ettinger B; Benet LZ
    J Urol; 1985 Nov; 134(5):871-3. PubMed ID: 4057369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of low-renin essential hypertension. Comparison of spironolactone and a hydrochlorothiazide-triamterene combination.
    Douglas JG; Hollifield JW; Liddle GW
    JAMA; 1974 Feb; 227(5):518-21. PubMed ID: 4589187
    [No Abstract]   [Full Text] [Related]  

  • 36. Delayed elimination of triamterene and its active metabolite in chronic renal failure.
    Knauf H; Möhrke W; Mutschler E
    Eur J Clin Pharmacol; 1983; 24(4):453-6. PubMed ID: 6861860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antihypertensive action of drug combination: Timolol, hydralazine, hydrochlorothiazide and triamterene.
    Pörsti P; Jalonen K; Ryysy L; Toivonen T; Viherkoski M
    Ann Clin Res; 1981 Feb; 13(1):6-10. PubMed ID: 7018363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of bioavailability on dose-response relationships.
    Goldman P
    Am J Med; 1984 Nov; 77(5A):47-51. PubMed ID: 6496559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dyazide-induced reversible acute renal failure associated with intracellular crystal deposition.
    Farge D; Turner MW; Roy DR; Jothy S
    Am J Kidney Dis; 1986 Dec; 8(6):445-9. PubMed ID: 3812475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of triamterene and its metabolite in man.
    Hasegawa J; Lin ET; Williams RL; Sörgel F; Benet LZ
    J Pharmacokinet Biopharm; 1982 Oct; 10(5):507-23. PubMed ID: 7166735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.